The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Amosartan® tab
Cozaar® plus pro tab
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- 20 aged or over
- Patients with blood pressure measured at Visit 1; 90mmHg≤MSDBP mmHg if on anti-hypertensive drugs, 95mmHg≤MSDBP mmHg if not on anti-hypertensive drugs
- Patients with blood pressure measured at Visit 2 were 90mmHg≤MSDBP mmHg (non-responder to Losartan 100mg for 4-week treatment)
Exclusion Criteria:
Patients with too high Blood pressure
•≥ sitSBP 20mmHg or ≥ sitDBP 10mmHg of variation in three measurements from the reference arm selected at Screening
- History of hypersensitivity to CCB ,Angiotensin II receptor blockers or Sulfonamide.
- Secondary hypertension or suspected to be
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Amosartan® tab
Cozaar® plus pro tab
Arm Description
Amlodipine 5mg /Losartan 100mg
Losartan 100mg/ HCTZ 12.5mg
Outcomes
Primary Outcome Measures
Change from baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)
Secondary Outcome Measures
Change from baseline in MSDBP
Change from baseline Mean Seated Systolic Blood Pressure (MSSBP)
Blood pressure responder rate
Rate of patients who achieved target blood pressure (MSSBP < 140 mmHg and MSDBP < 90 mmHg), or MSSBP decrease > 20 mmHg from baseline or MSDBP decrease > 10 mmHg from baseline.
Full Information
NCT ID
NCT01828359
First Posted
April 7, 2013
Last Updated
April 9, 2013
Sponsor
Hanmi Pharmaceutical Company Limited
1. Study Identification
Unique Protocol Identification Number
NCT01828359
Brief Title
The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.
Official Title
An Eight-week, Randomized, Double-blind Multicenter Study to Compare the Efficacy and Safety of Amosartan® Tab 5/100mg Versus Cozaar® Plus Pro Tab in Patients With Essential Hypertension Uncontrolled With Losartan 100mg Monotherapy
Study Type
Interventional
2. Study Status
Record Verification Date
April 2013
Overall Recruitment Status
Completed
Study Start Date
August 2010 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hanmi Pharmaceutical Company Limited
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the blood pressure lowering effects of an amlodipine/losartan combination treatment and losartan/Hydrochlorothiazide combination treatment in patients with essential hypertension uncontrolled with losartan 100mg monotherapy.
Detailed Description
Quality assurance plan was implemented by site monitoring, including data validation and registry procedures and Source data verification to assess the accuracy, completeness by comparing the data to external data sources (medical records and paper case report forms).
Data dictionary contains the registry, including the source of the variable, coding information (MedDRA ver12.0), and normal ranges.
Statistical analysis were performed using SAS® Version 9.2, SAS institute, Cary, NC, USA
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
199 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Amosartan® tab
Arm Type
Experimental
Arm Description
Amlodipine 5mg /Losartan 100mg
Arm Title
Cozaar® plus pro tab
Arm Type
Active Comparator
Arm Description
Losartan 100mg/ HCTZ 12.5mg
Intervention Type
Drug
Intervention Name(s)
Amosartan® tab
Other Intervention Name(s)
Amlodipine 5mg /Losartan 100mg
Intervention Description
comparison of different combination of anti-hypertension drug
Intervention Type
Drug
Intervention Name(s)
Cozaar® plus pro tab
Other Intervention Name(s)
Losartan 100mg/ HCTZ 12.5mg
Intervention Description
comparison of different combination of anti-hypertension drug
Primary Outcome Measure Information:
Title
Change from baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)
Time Frame
Baseline, Week 8
Secondary Outcome Measure Information:
Title
Change from baseline in MSDBP
Time Frame
Baseline, week 4
Title
Change from baseline Mean Seated Systolic Blood Pressure (MSSBP)
Time Frame
Baseline, Week 4 and 8
Title
Blood pressure responder rate
Description
Rate of patients who achieved target blood pressure (MSSBP < 140 mmHg and MSDBP < 90 mmHg), or MSSBP decrease > 20 mmHg from baseline or MSDBP decrease > 10 mmHg from baseline.
Time Frame
Baseline, Week 4 and 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
20 aged or over
Patients with blood pressure measured at Visit 1; 90mmHg≤MSDBP mmHg if on anti-hypertensive drugs, 95mmHg≤MSDBP mmHg if not on anti-hypertensive drugs
Patients with blood pressure measured at Visit 2 were 90mmHg≤MSDBP mmHg (non-responder to Losartan 100mg for 4-week treatment)
Exclusion Criteria:
Patients with too high Blood pressure
•≥ sitSBP 20mmHg or ≥ sitDBP 10mmHg of variation in three measurements from the reference arm selected at Screening
History of hypersensitivity to CCB ,Angiotensin II receptor blockers or Sulfonamide.
Secondary hypertension or suspected to be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Taehoon Ahn, Ph.D.
Organizational Affiliation
Gachon University Gil Medical Center
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.
We'll reach out to this number within 24 hrs